Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 869-875

  Sáez Llorens, Xavier ^a   Macias, Mercedes ^b   Maiya, Padmanabha ^c   Pineros, Juan ^d   Jafri, Hasan S ^e   Chatterjee, Archana ^f   Ruiz, Gloria ^g   Raghavan, Janaki ^h   Bradshaw, Susan K ⁱ   Kartsonis, Nicholas A ⁱ   Sun, Peng ⁱ   Strohmaier, Kim M ⁱ   Fallon, Marissa ⁱ   Bi, Sheng ⁱ   Stone, Julie A ⁱ   Chow, Joseph W ⁱ  

^a Hospital del Niño   (Panama)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c M S RAMAIAH MEDICAL COLLEGE   (India)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^h Kanakamna Ramachandra Hospital   (India)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GESTATIONAL AGE; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; HYPERVENTILATION; INFANT; INTESTINE PERFORATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTICENTER STUDY; NECROTIZING ENTEROCOLITIS; NEWBORN; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; BODY SURFACE AREA; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; ECHINOCANDINS; FEMALE; FEVER; HUMANS; HYPERTENSION; HYPERVENTILATION; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES;

EID: 62949113674     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00868-08     Document Type: Article

References (21)

1. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46:451-457.
2. Benjamin, D. K., Jr., B. J. Stall, A. A. Fanaroff, S. A. McDonald, W. Oh, R. D. Higgins, S. Duara, K. Poole, A. Laptook, and R. Goldberg. 2006. Neonatal candidiasis among extremely low birthweight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 and 22 months. Pediatrics 117:84-92.
3. Bi, S., M. S. Schwartz, R. B. Desai, A. R. Miller, and B. K. Matuszewski. 2005. A semi-automated procedure for the determination of caspofungin in human plasma using solid-phase extraction and HPLC with fluorescence detection using secondary ionic interactions to obtain a highly purified extract. J. Liq Chromatogr.'Relat. Technol. 28:2895-2908.
4. Bliss, J. M., M. Wellington, and F. Gigliotti. 2003. Antifungal pharmacotherapy for neonatal candidiasis. Semin. Perinatol. 27:365-374.
5. Cornely, O., M. Lasso, R. Betts, N. Klimko, J. Vazquez, G. Dobb, J. Velez, A. Williams-Diaz, J. Lipka, A. Taylor, C. Sable, and N. Karfcsonis. 2007. Caspofungin for the treatment of less common forms of invasive candidiasis. J. Antimicrob. Chemother. 60:363-369.
6. DiNubile, M. J., R. J- Lupinacci, R. S. Berman, and C. A. Sable. 2002. Response and relapse rates of candidal esophagitis in HIV-infected patients treated with caspofungin. AIDS Res. Hum. Retrovir. 18:903-908.
7. Fernandez, M., E. H. Moylett, D. E. Noyola, and C. J. Baker. 2000. Candidal meningitis in neonates: a 10-year review. Clin. Infect. Dis. 31:458-463.
8. Mora-Duarte, J., R, Betts, C. Rotstein, A. L. Colombo, L, Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
9. Mosteller, R. D. 1987. Simplified calculation of body surface area. N. Engl. J. Med. 317:1098.
10. Natarajan, G., M. Lulic-Botica, C. Rongkavilit, A. Pappas, and M, Bedard. 2005. Experience with caspofungin in the treatment of persistent fungemia in neonates. J. Perinatol. 25:770-777.
11. Neely, M., H. S. Jafri, N. Seibel, K. Knapp, P. C. Adamson, S. K. Bradshaw, K. M. Strohmaier, P. Sun, S. Bi, M. F. Dockendorf, J. A. Stone, and N. A. Kartsonis. Pharmacokinetics and safety of caspofungin in older infants and taddlers. Antimicrob. Agents Chemother., in press.
12. Odio, C. M., R. Araya, L E. Pinto, C. I. Castro, S. Vasquez, B. Alfaro, A. Saenz, M. L. Herrera, and T. J. Walsh. 2004. Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. 23:1093-1097.
13. Sandhu, P., W. Lee, X. Xu, B. F. Leake, M. Yamazaki, J. A. Stone, J. H. Lin, P. G. Pearson, and R. B. Kim. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33:676-682.
14. Schwartz, M., W. Kline, and B. Matuszewski. 1997. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal. Chim. Acta 352:299-307.
15. Smith, P. B., W. J. Steinbach, C. M. Gotten, W. A. Schell, J. A. Perfect, T. J. Walsh, and D. K. Benjamin, Jr. 2007. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J. Perinatol. 27:127-129.
16. Stoll, B. J., and N. Hansen. 2003. Infections in VLBW infants: studies from the N1CHD Neonatal Research Network. Semin. Perinatol. 27:293-301.
17. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. chwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
18. Stone, J. A., X. Xu, G. A. Winchell, P. J. Deutsch, P. G. Pearson, E. M. Migoya, G. C. Mistry, L. Xi, A. Miller, P. Sandhu, R. Singh, F. deLuna, S. C. Dilzer, and K. C. Lasseter. 2004. Disposition of caspofungin: role of distribution in determining plasma pharmacokinetics. Antimicrob. Agents Chemother. 48:815-823.
19. Villaneuva, A., E. G. Arathoon, E. Gotuzzo, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33:1529-1535.
20. Walsh, T, J., P. C. Adamson, N. L. Seibel, P. M, Flynn, M. N, Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545.
21. Yalaz, M., M. Akisu, S. Hilmioglu, S. Calkavur, B. Cakmak, and N. Kultursay. 2006. Successful caspofungin treatment of multidrug resistant Candida parapsilosis septicaemia in an extremely low birth weight neonate. Mycoses 49:242-245.